Literature DB >> 8138243

Enzyme inhibitory autoantibodies to pyruvate dehydrogenase complex in primary biliary cirrhosis differ for mammalian, yeast and bacterial enzymes: implications for molecular mimicry.

K L Teoh1, I R Mackay, M J Rowley, S P Fussey.   

Abstract

Primary biliary cirrhosis is a chronic autoimmune disease in which serum autoantibodies against the mitochondrial 2-oxo acid dehydrogenase enzyme complexes (M2 antibodies) are regularly present. Molecular mimicry of host proteins by bacterial counterparts is a suggested explanation for the origin of these autoantibodies. We tested this hypothesis by measuring the functional reactivity of serum autoantibodies by means of an enzyme inhibition assay against pyruvate dehydrogenase complex from different sources: mammalian, Saccharomyces cerevisiae and Escherichia coli. The 10 primary biliary cirrhosis sera all reacted on immunofluorescence study for M2 antibodies and on immunoblotting with the pyruvate dehydrogenase complex E2 subunit from each of the three enzymes, but there were strikingly different inhibitory capacities. The primary biliary cirrhosis sera were highly inhibitory for mammalian pyruvate dehydrogenase complex (10 of 10 inhibitory; mean level of inhibition, 99%), moderately inhibitory for yeast pyruvate dehydrogenase complex (10 of 10 inhibitory; mean level, 70%) and weakly inhibitory for Escherichia coli pyruvate dehydrogenase complex (4 of 10 inhibitory; mean level, 26%). Thus, with a functional assay that depends on epitope recognition of primary biliary cirrhosis sera, cross-reactivity between mammalian and bacterial pyruvate dehydrogenase complex enzymes is low and molecular mimicry, at least at the B-lymphocyte level, is not supported.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8138243

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  9 in total

1.  Anti-Saccharomyces cerevisiae antibodies in primary biliary cirrhosis.

Authors:  Wahiba Sakly; Moncef Jeddi; Ibtissem Ghedira
Journal:  Dig Dis Sci       Date:  2007-11-30       Impact factor: 3.199

Review 2.  Pathogenesis of primary biliary cirrhosis: a unifying model.

Authors:  Elias Kouroumalis; George Notas
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

3.  Ursodeoxycholic acid treatment lowers the serum level of antibodies against pyruvate dehydrogenase and influences their inhibitory capacity for the enzyme complex in patients with primary biliary cirrhosis.

Authors:  K E Kisand; A L Karvonen; M Vuoristo; M Färkkilä; J Lehtola; J Inkovaara; K V Kisand; T Miettinen; K Krohn; R Uibo
Journal:  J Mol Med (Berl)       Date:  1996-05       Impact factor: 4.599

4.  Identification of novel molecules and pathogenic pathways in primary biliary cirrhosis: cDNA array analysis of intrahepatic differential gene expression.

Authors:  N A Shackel; P H McGuinness; C A Abbott; M D Gorrell; G W McCaughan
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

5.  Catalytic domain of PDC-E2 contains epitopes recognized by antimitochondrial antibodies in primary biliary cirrhosis.

Authors:  Sandra Braun; Christoph Berg; Sandra Buck; Michael Gregor; Reinhild Klein
Journal:  World J Gastroenterol       Date:  2010-02-28       Impact factor: 5.742

6.  Bcl-2-dependent oxidation of pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen, during apoptosis.

Authors:  J A Odin; R C Huebert; L Casciola-Rosen; N F LaRusso; A Rosen
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

Review 7.  Autoantigens in primary biliary cirrhosis.

Authors:  D E Jones
Journal:  J Clin Pathol       Date:  2000-11       Impact factor: 3.411

Review 8.  The immunology of primary biliary cirrhosis: the end of the beginning?

Authors:  J M Palmer; J A Kirby; D E J Jones
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

9.  Autoimmunity in chronic active Helicobacter hepatitis of mice. Serum antibodies and expression of heat shock protein 70 in liver.

Authors:  J M Ward; R E Benveniste; C H Fox; J K Battles; M A Gonda; J G Tully
Journal:  Am J Pathol       Date:  1996-02       Impact factor: 4.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.